The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Results for its new CagriSema drug, while promising, fell below expectations, sending shares of the pharmaceutical giant down ...

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

Novo Nordisk (NVO) increased valuation gap with Eli Lilly (LLY) after its Phase 3 data for next-gen weight loss drug ...

On Friday, the federal agency green-lighted Eli Lilly’s Zepbound drug for the use, approving a prescription medicine suited for adults suffering from moderate to severe obstructive sleep apnea (OSA) ...

Eli Lilly is now comfortably ahead of Novo Nordisk in the race to dominate the market for obesity treatments.

The updates from clinical trials of Eli Lilly's competitors in the obesity market were largely underwhelming this year. See ...

Analyst Akash Tewari from Jefferies maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) and keeping the price target at $994.00. Discover top-rated stocks from highly ranked analysts ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss ...

We recently compiled a list of the 6 Stocks Jim Cramer Talked About This Week. In this article, we are going to take a look ...